Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: Clinical correlation

Journal of Gastroenterology and Hepatology (Australia)

Volumn 12, Issue 8, 1997, Pages 569-575

  Chou, Yuh Yu ^a   Cheng, Ann Lii ^a   Hsu, Hey Chi ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Chemotherapy; Hepatocellular carcinoma; Immunohistochemical study; Multidrug resistance gene; P glycoprotein; p53

Indexed keywords

DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; MONOCLONAL ANTIBODY; PROTEIN P53; TAMOXIFEN;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CELL CARCINOMA; MALE; MULTIDRUG RESISTANCE; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

EID: 0030756881     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1997.tb00487.x     Document Type: Article

References (32)

1. Nerenstone SR, Ihde DC, Friedman MA. Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat. Rev. 1988; 15: 1-31.
2. Cheng AL, Chen YC, Yeh KH, Chuang SE, Chen BR, Chen DS. Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma. Cancer 1996; 77: 872-7.
3. Melia WM, Johnson PJ, Williams R. Induction of remission in hepatocellular carcinoma: (a comparison of VP-16 with adriamycin. Cancer 1983; 51: 206-10.
4. Teeter LD, Hsu HC, Curley SA, Tong MJ, Tien Kuo M. Expression of multidrug resistance (P-glycoprotein) MDR1 and MDR2 genes in human hepatocellular carcinoma and liver metastases of colonic tumors. Int. J. Oncol. 1993; 2: 73-80.
5. Huang CC, Wu MC, Su GW et al. Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. J. Natl Cancer Inst. 1992; 84: 262-4.
6. Pastan I, Gottesman M. Multidrug resistance in human cancer. N. Engl. J. Med. 1987; 316: 1388-93.
7. Gerlach JH, Kartner N, Bell DR, Ling V. Multidrug resistance. Cancer Surv. 1986; 5: 25-16.
8. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human 'MDR1' gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl Acad. Sci. USA 1987; 84: 3004-8.
9. Chen CJ, Chin JE, Ueda K et al. Internal duplication and homology with bacterial transport proteins in the mdr (P glycoprotein) gene from multidrug-resistant human cells. Cell 1986; 47: 381-9.
10. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl Acad. Sci. USA 1987; 84: 7735-8.
11. Gatmaitan ZC, Arias IM. Structure and function of P-glycoprotein in normal liver and small intestine. Adv. Pharmacol. 1993; 24: 77-97.
12. Kanamaru H, Kakehi Y, Yoshida O, Nakanishi S, Pastan I, Gottesman M. MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversals of doxorubicin resistance by quinidine in tumor explants. J. Natl Cancer Inst. 1989; 81: 844-9.
13. Flynn SD, Murren JR, Kirby WM, Honig J, Kan L, Kinder BK. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery 1992; 112: 981-6.
14. Goldstein LJ, Galski H, Fojo A et al. Expression of a multidrug resistance gene in human cancers. J. Natl Cancer Inst. 1989; 81: 116-24.
15. Chan HSL, Haddad G, Thorner PG et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N. Engl. J. Med. 1991; 325: 1608-14.
16. Cheng AL, Su IJ, Chen YC, Lee TH, Wang CH. Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphoma: The possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors. J. Clin. Oncol. 1993; 11: 109-15.
17. Chan HSL, Thorner PS, Haddad G, Ling V. Immunohistochemical detection of glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J. Clin. Oncol. 1990; 8: 689-704.
18. Kelley DJ, Pavelic ZP, Gapany M et al. Detection of P-glycoprotein in squamous cell carcinomas of the head and neck. Arch. Otolaryngol. Head Neck Surg. 1993; 119: 411-4.
19. Baldini N, Scotlandi K, Baranti-Brodano G et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N. Engl. J. Med. 1995; 333: 1380-5.
20. Itsubo M, Ishikawa T, Toda G, Tanaka M. Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma. Cancer 1994; 73: 298-303.
21. Nagasue N, Dhar DK, Makino Y, Yoshimura H, Nakamura T. Overexpression of P-glycoprotein in adenomatous hyperplasia of human liver with cirrhosis. J. Hepatol. 1995; 22: 197-201.
22. Levine A, Momand J, Finlay C. The p53 tumor suppressor gene. Nature 1991; 351: 453-6.
23. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 1992; 255: 459-62.
24. Goldsmith ME, Gudas JM, Schneider E, Cowan KH. Wild type p53 stimulates expression from human multidrug resistance promoter in a p53-negative cell line. J. Biol. Chem. 1995; 270: 1894-8.
25. Scheper RJ, Bulte JWM, Brakkee JGP et al. Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multidrug-resistance. Int. J. Cancer 1988; 42: 389-94.
26. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue section. J. Histochem. Cytochem. 1991; 39: 741-8.
27. Hsu HC, Tseng HJ, Lai PL, Lee PH, Peng SY. Expression of p53 gene in 184 unifocal hepatocellular carcinoma: association with tumor growth and invasiveness. Cancer Res. 1993; 53: 4691-4.
28. Mizoguchi T, Yamada K, Furukawa T et al. Expression of the MDR1 gene in human gastric and colorectal carcinomas. J. Natl Cancer Inst. 1990; 82: 1679-83.
29. Schneider J, Romero H. Correlation of P-glycoprotein overexpression and cellular prognostic factors in formalin-fixed, paraffin-embedded tumor samples from breast cancer patients. Anticancer Res. 1995; 15: 1117-22.
30. Hsu HC, Wu TT, Wu MZ, Sheu JC, Lee CS, Chen DS. Tumor invasiveness and prognosis in resected hepatocellular carcinoma: clinical and pathogenetic implications. Cancer 1988; 61: 2095-9.
31. Preudhomme C, Lepelley P, Vachee A et al. Relationship between p53 gene mutations and multidrug resistance (mdrl) gene expression in myelodysplastic syndromes. Leukemia 1993; 7: 1888-90.
32. De Angelis P, Stokke T, Smedshammer L et al. P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo. Br. J. Cancer 1995; 72: 307-11.